Laksh Aithani, CHARM Therpeutics CEO

Big names, big back­ers: David Bak­er joins Or­biMed, F-Prime, Khosla and oth­ers as pro­tein-lig­and biotech launch­es

David Bak­er, one of the biggest names in the pro­tein de­sign space with mul­ti­ple sci­en­tif­ic prizes, his own in­sti­tute at the Uni­ver­si­ty of Wash­ing­ton and a few com­pa­nies to his name, is throw­ing his weight be­hind an­oth­er biotech — one that seeks to take his famed work in pro­tein fold­ing and ex­tend it fur­ther in­to drug dis­cov­ery and de­vel­op­ment.

CHARM Ther­a­peu­tics, based out of the UK, an­nounced its launch bright and ear­ly Thurs­day morn­ing, with $50 mil­lion in eq­ui­ty fi­nanc­ing. CEO Laksh Aithani de­clined to give specifics on the fi­nanc­ing run­way, but he did say that, “His­tor­i­cal­ly, these sorts of Se­ries A rounds have been able to bankroll com­pa­nies of­ten to a sort of de­vel­op­ment can­di­date stage.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.